Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Gelijkaardige items

• Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
  door: Zugazagoitia, Jon, et al.
  Gepubliceerd in: (2017)
• Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
  door: Fala, Loretta
  Gepubliceerd in: (2016)
• Locally advanced non-small cell lung cancer treatment: another step forward
  door: Filosso, Pier Luigi, et al.
  Gepubliceerd in: (2017)
• Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
  door: Chigutsa, E, et al.
  Gepubliceerd in: (2017)
• Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
  door: Paz-Ares, L., et al.
  Gepubliceerd in: (2016)